CANbridge Announces Financial Results and Corporate Updates for Six Months Ended June 30, 2022

First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2   Trial for the Treatment of Gaucher Disease in China

First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China

  -  China Study is Part of Global EMBARK Study

CANbridge Forms Scientific Advisory Board to Guide Global Development of CAN106 in Complement-mediated Diseases

CANbridge Appoints Industry Leader Edward Hu to the Board

CANbridge CAN106 Phase 1 Data Presented at the European Hematology Association 2022 Congress

CANbridge Pharmaceuticals to Present at the Jefferies Global Healthcare Conference 2022

CANbridge Pharmaceuticals to Participate in the Morgan Stanley Virtual China Summit 2022

CANbridge-UMass Chan Medical School Gene Therapy Research Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

First Study from CANbridge UMass Collaboration Shows Novel Gene Therapy Holds Promise for Spinal Muscular Atrophy Clinical Applications